Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
sorafenib + tegafur-uracil
- Development stage
- Unknown
- Lead developer
- Bayer
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Sorafenib + tegafur-uracil is a combination therapy that has been investigated for the treatment of advanced hepatocellular carcinoma (HCC). Sorafenib is a multi-kinase inhibitor with anti-angiogenic activity that was approved for the treatment of advanced HCC. Tegafur-uracil (UFT) is an oral fluoropyrimidine that provides metronomic chemotherapy. The combination was studied based on preclinical evidence suggesting that metronomic chemotherapy using tegafur-uracil could enhance the anti-tumor effect of anti-angiogenic agents like sorafenib.
- Other names
- sorafenib + UFTsorafenib + tegafur/uracilsorafenib + UFUR
02
Targets
RAF1 (c-Raf-1 (Y340D/Y341D))KIT (c-KIT proto-oncogene receptor tyrosine kinase)TS (Thymidylate synthase)PDGFRB (Platelet-derived growth factor receptor beta)VEGFR2 (Vascular endothelial growth factor receptor 2)FLT3 (Fms related receptor tyrosine kinase 3)
Beyond the preview
Go deeper on sorafenib + tegafur-uracil.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on sorafenib + tegafur-uracil.